Related Experiment Video
Updated: Jan 11, 2026
Assessment of Acute Wound Healing using the Dorsal Subcutaneous Polyvinyl Alcohol Sponge Implantation and Excisional Tail Skin Wound Models.
Published on: March 25, 2020
Comparing the wound healing properties of two antibacterial peptides, CM11 and FR7, using a rat model with an
Reza Mirnejad1, Hamid Heydari1, Mehrdad Moosazadeh Moghaddam2
1Molecular Biology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Objective:
Antimicrobial peptides (AMPs) have received attention in recent years for dealing with wound infections. This study aimed to evaluate the antibacterial activity of antimicrobial peptides FR7 and CM11 against methicillin-resistant Staphylococcus aureus (MRSA) strains in vitro and investigate their wound healing properties in vivo.
Methods:
The minimum inhibitory concentrations (MIC) of these peptides were determined using the microdilution method. Both peptides were evaluated for toxicity in L929 cells. Their antimicrobial activity and wound healing potency were tested in vivo. Wounds infected with MRSA were treated with the peptide gel or Mupirocin (positive control) or untreated (negative control). Wound healing was assessed by measuring wound contraction (days 3, 7, 10, 14, 17 and 21) and histopathological changes (days 3, 7, 14 and 21).
Results:
MRSA strain was inhibited by both AMPs at 8 μg/ml with minimal cytotoxicity to L929 cells. In vivo analysis showed higher wound contraction in the AMPs-treated groups compared to controls, with CM11 showing better results than FR7. Histopathological analysis indicated better wound healing in the CM11-treated group.
Conclusion:
This study demonstrates the antibacterial and wound healing potential of CM11 and FR7 peptides, with CM11 showing greater efficacy and potential for developing treatments for wound infections, especially those caused by antibiotic-resistant strains.
Insights
Antimicrobial peptides (AMPs) FR7 and CM11 show promise for treating wound infections caused by methicillin-resistant Staphylococcus aureus (MRSA). CM11 demonstrated superior antibacterial and wound healing capabilities in vivo.
Area of Science:
- Biochemistry
- Microbiology
- Dermatology
Background:
- Antimicrobial peptides (AMPs) are emerging as a vital strategy against wound infections.
- Antibiotic resistance, particularly from strains like methicillin-resistant Staphylococcus aureus (MRSA), necessitates novel therapeutic approaches.
- AMPs offer a potential solution due to their broad-spectrum activity and unique mechanisms of action.
Purpose of the Study:
- To assess the in vitro antibacterial efficacy of AMPs FR7 and CM11 against MRSA.
- To evaluate the in vivo wound healing potential of FR7 and CM11.
- To determine the safety profile of these AMPs in mammalian cells.
Main Methods:
- Minimum inhibitory concentrations (MIC) were determined using microdilution assays.
- Cytotoxicity was assessed in L929 cell lines.
- In vivo wound models infected with MRSA were treated with peptide gels, with outcomes measured by wound contraction and histopathological analysis.
Main Results:
- Both FR7 and CM11 inhibited MRSA at 8 μg/ml with low cytotoxicity.
- In vivo studies revealed enhanced wound contraction in AMP-treated groups compared to controls.
- The CM11 peptide group exhibited superior wound healing and contraction compared to the FR7 group and controls.
Conclusions:
- AMPs FR7 and CM11 possess significant antibacterial and wound healing properties.
- CM11 demonstrates greater efficacy, highlighting its potential for treating MRSA-induced wound infections.
- These findings support the development of novel peptide-based therapies for challenging wound infections.
